Compare ALNY & URI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALNY | URI |
|---|---|---|
| Founded | 2002 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Diversified Commercial Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.1B | 63.1B |
| IPO Year | 2004 | 1997 |
| Metric | ALNY | URI |
|---|---|---|
| Price | $472.35 | $815.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 27 | 13 |
| Target Price | $483.89 | ★ $983.58 |
| AVG Volume (30 Days) | ★ 931.6K | 636.6K |
| Earning Date | 10-30-2025 | 10-22-2025 |
| Dividend Yield | N/A | ★ 0.88% |
| EPS Growth | N/A | ★ 1.51 |
| EPS | 0.33 | ★ 38.83 |
| Revenue | $3,210,070,000.00 | ★ $15,986,000,000.00 |
| Revenue This Year | $65.55 | $6.16 |
| Revenue Next Year | $41.48 | $6.11 |
| P/E Ratio | $1,434.84 | ★ $20.95 |
| Revenue Growth | ★ 53.24 | 6.73 |
| 52 Week Low | $205.87 | $525.91 |
| 52 Week High | $495.55 | $1,021.47 |
| Indicator | ALNY | URI |
|---|---|---|
| Relative Strength Index (RSI) | 60.74 | 40.52 |
| Support Level | $420.30 | $769.88 |
| Resistance Level | $467.73 | $823.01 |
| Average True Range (ATR) | 15.46 | 21.41 |
| MACD | 2.81 | 4.18 |
| Stochastic Oscillator | 87.88 | 45.10 |
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
United Rentals is the world's largest equipment rental company, principally operating in the US and Canada. It has 16% share in a highly fragmented market serving general industrial (49%), commercial construction (46%), and residential construction (5%). The company operates a $21 billion fleet of equipment, including aerial platforms, forklifts, excavators, trucks, power generators, and various other materials serving local and national accounts from nearly 1,600 locations in North America and 100 abroad. It has pursued a strategy of bundling specialty rental capabilities to offer its customers more advanced solutions in addition to its core equipment rental business, supporting its ambitions to become a one-stop shop for customers and enhance and maintain its margin profile.